I-Mab ADR (IMAB): Price and Financial Metrics
GET POWR RATINGS... FREE!
IMAB POWR Grades
- Growth is the dimension where IMAB ranks best; there it ranks ahead of 94.55% of US stocks.
- IMAB's strongest trending metric is Growth; it's been moving up over the last 26 weeks.
- IMAB ranks lowest in Quality; there it ranks in the 2nd percentile.
IMAB Stock Summary
- IMAB's one year PEG ratio, measuring expected growth in earnings next year relative to current common stock price is 0.54 -- higher than merely 5.04% of US-listed equities with positive expected earnings growth.
- In terms of twelve month growth in earnings before interest and taxes, I-MAB is reporting a growth rate of -529.88%; that's higher than just 3.23% of US stocks.
- Revenue growth over the past 12 months for I-MAB comes in at -92.84%, a number that bests merely 1.13% of the US stocks we're tracking.
- Stocks that are quantitatively similar to IMAB, based on their financial statements, market capitalization, and price volatility, are TUYA, ENVX, PACB, EFTR, and MVIS.
- Visit IMAB's SEC page to see the company's official filings. To visit the company's web site, go to www.i-mabbiopharma.com.
IMAB Stock Price Chart Interactive Chart >
IMAB Price/Volume Stats
|Current price||$4.07||52-week high||$57.21|
|Prev. close||$3.67||52-week low||$3.25|
|Day high||$4.14||Avg. volume||854,204|
|50-day MA||$3.84||Dividend yield||N/A|
|200-day MA||$9.63||Market Cap||338.21M|
I-Mab ADR (IMAB) Company Bio
I-Mab, a clinical stage biopharmaceutical company, engages in the discovery, development, and commercialization of novel or highly differentiated biologics to treat diseases with unmet medical needs, primarily cancers and autoimmune disorders worldwide. It is developing TJ202, a CD38 antibody in Phase III clinical trials to treat multiple myeloma and autoimmune diseases; TJ101, a long-acting human growth hormone that is in Phase II clinical trials to treat pediatric growth hormone deficiency; and TJ301, a IL-6 blocker in Phase II clinical trials for the treatment of ulcerative colitis and other autoimmune diseases. The company's product candidates in Phase I clinical trials include Enoblituzumab, a humanized B7-H3 antibody to treat immuno-oncology; TJ107, a long-acting recombinant human IL-7 to treat cancer treatment-related lymphopenia and cancer immunotherapy; TJC4, a CD47 monoclonal antibody with RBC-sparing differentiation; TJD5, a CD73 antibody for cancer treatment; and TJM2, a GM-CSF monoclonal antibody for rheumatoid arthritis and CAR-T-related therapies. Its product candidates in pre-clinical development comprise TJ210, an antibody targeting myeloid derived suppressor cells in cancers and autoimmune diseases; and TJX7, a novel CXCL13 antibody for autoimmune diseases. The company was founded in 2014 and is headquartered in Shanghai, the People's Republic of China.
Most Popular Stories View All
IMAB Latest News Stream
|Loading, please wait...|
IMAB Latest Social Stream
View Full IMAB Social Stream
Latest IMAB News From Around the Web
Below are the latest news stories about I-MAB that investors may wish to consider to help them evaluate IMAB as an investment opportunity.
I-Mab ( NASDAQ:IMAB ) First Half 2022 Results Key Financial Results Revenue: CN¥51.9m (up 192% from 1H 2021). Net loss...
I-Mab (the "Company") (Nasdaq: IMAB), a clinical-stage biopharmaceutical company committed to the discovery, development, and commercialization of novel biologics, today announced that two poster presentations featuring preclinical and translational research data of lemzoparlimab, will be presented at the 64th American Society of Hematology (ASH) Annual Meeting, taking place December 10-13, 2022, in New Orleans, Louisiana.
I-Mab Announces Poster Presentations of CD47 Antibody Lemzoparlimab and CD73 Antibody Uliledlimab at SITC 2022
I-Mab (the "Company") (Nasdaq: IMAB), a clinical-stage biopharmaceutical company committed to the discovery, development, and commercialization of novel biologics, today announced that the Company will present new preclinical data of its core assets lemzoparlimab and uliledlimab, respectively, at the 37th Society for Immunotherapy of Cancer's (SITC) Annual Meeting in Boston, MA, as well as virtually November 8-12, 2022.
I-Mab Announces Approval from China CDE to Initiate Phase 3 Registrational Study of Lemzoparlimab in Combination with Azacitidine in Higher-Risk Myelodysplastic Syndrome
I-Mab (the "Company") (Nasdaq: IMAB), a clinical-stage biopharmaceutical company committed to the discovery, development, and commercialization of novel biologics, today announced that it has successfully completed an End-of-Phase 2 (EoP2) meeting with the Center for Drug Evaluation (CDE) of China's National Medical Products Administration (NMPA), and has obtained approval from the CDE to initiate a Phase 3 registrational trial evaluating lemzoparlimab, a novel CD47 antibody, in combination with
I-Mab Announces Positive Phase 2 Data of Lemzoparlimab in Combination with Azacitidine (AZA) in Patients with Higher Risk Myelodysplastic Syndrome at ESMO 2022
I-Mab (the "Company") (Nasdaq: IMAB), a clinical-stage biopharmaceutical company committed to the discovery, development, and commercialization of novel biologics, today announces encouraging data from its Phase 2 clinical trial (NCT04202003) of lemzoparlimab (also known as TJC4) in combination with azacitidine (AZA) in patients with newly diagnosed higher risk myelodysplastic syndrome (HR-MDS), presented in an oral presentation on September 10 at the European Society for Medical Oncology (ESMO)
IMAB Price Returns